Home » FDA Places Clinical Hold on Agios’ Development Anemia Disorder Drug
FDA Places Clinical Hold on Agios’ Development Anemia Disorder Drug
Agios is discontinuing the development of an anemia disorder drug after the FDA placed a clinical hold on trials for the candidate, prompting the company shift its focus to another candidate.
The FDA’s decision to stop the clinical trials came after a subject developed liver disease while taking a 300mg tablet of the candidate.
The company plans to work on developing a less potent anemia disorder candidate that has proven more successful candidate in studies.
Upcoming Events
-
07May
-
14May
-
30May